GALLIUM GA 68 GOZETOTIDE Drug Patent Profile
✉ Email this page to a colleague
When do Gallium Ga 68 Gozetotide patents expire, and when can generic versions of Gallium Ga 68 Gozetotide launch?
Gallium Ga 68 Gozetotide is a drug marketed by Ionetix, Radiomedix, Univ Ca Los Angeles, and Univ Of Ca San Fran. and is included in four NDAs.
The generic ingredient in GALLIUM GA 68 GOZETOTIDE is gallium ga-68 gozetotide. Six suppliers are listed for this compound. Additional details are available on the gallium ga-68 gozetotide profile page.
US Patents and Regulatory Information for GALLIUM GA 68 GOZETOTIDE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ionetix | GALLIUM GA 68 GOZETOTIDE | gallium ga-68 gozetotide | SOLUTION;INTRAVENOUS | 219189-001 | May 14, 2026 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Univ Of Ca San Fran | GALLIUM GA 68 GOZETOTIDE | gallium ga-68 gozetotide | SOLUTION;INTRAVENOUS | 212643-001 | Dec 1, 2020 | AP | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Radiomedix | GALLIUM GA 68 GOZETOTIDE | gallium ga-68 gozetotide | SOLUTION;INTRAVENOUS | 216410-001 | Jun 8, 2026 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Univ Ca Los Angeles | GALLIUM GA 68 GOZETOTIDE | gallium ga-68 gozetotide | SOLUTION;INTRAVENOUS | 212642-001 | Dec 1, 2020 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
